Critical values of CD69 and CD154 suppression by ex vivo–expanded Tregs as a diagnostic test for inhibition of proliferation at 96 hours
| Marker and values . | Sensitivity (95% CI) . | Specificity (95% CI) . | PPV, % . | NPV, % . | LR+ . | LR− . |
|---|---|---|---|---|---|---|
| CD69 | ||||||
| Lower quartile: > 15.5% | 94 (69-100) | 44 (23-67) | 63 | 88 | 1.7 | 0.1 |
| Median: > 24.1% | 63 (39-82) | 69 (44-86) | 67 | 65 | 2.0 | 0.5 |
| Upper quartile: > 40.1% | 25 (10-50) | 81 (56-94) | 57 | 52 | 1.3 | 0.8 |
| Minimum cost: 43.8% | 13 (3-38) | 94 (69-100) | 67 | 52 | 2.0 | 0.9 |
| CD154 | ||||||
| Lower quartile: > 29.6% | 92 (73-98) | 44 (26-63) | 63 | 83 | 1.6 | 0.2 |
| Median: > 45.0% | 71 (51-85) | 78 (58-91) | 77 | 72 | 3.2 | 0.4 |
| Upper quartile: > 56.0% | 41 (32-69) | 96 (77-100) | 91 | 61 | 9.5 | 0.6 |
| Minimum cost: 54% | 50 (32-69) | 96 (77-100) | 92 | 65 | 11.5 | 0.5 |
| Marker and values . | Sensitivity (95% CI) . | Specificity (95% CI) . | PPV, % . | NPV, % . | LR+ . | LR− . |
|---|---|---|---|---|---|---|
| CD69 | ||||||
| Lower quartile: > 15.5% | 94 (69-100) | 44 (23-67) | 63 | 88 | 1.7 | 0.1 |
| Median: > 24.1% | 63 (39-82) | 69 (44-86) | 67 | 65 | 2.0 | 0.5 |
| Upper quartile: > 40.1% | 25 (10-50) | 81 (56-94) | 57 | 52 | 1.3 | 0.8 |
| Minimum cost: 43.8% | 13 (3-38) | 94 (69-100) | 67 | 52 | 2.0 | 0.9 |
| CD154 | ||||||
| Lower quartile: > 29.6% | 92 (73-98) | 44 (26-63) | 63 | 83 | 1.6 | 0.2 |
| Median: > 45.0% | 71 (51-85) | 78 (58-91) | 77 | 72 | 3.2 | 0.4 |
| Upper quartile: > 56.0% | 41 (32-69) | 96 (77-100) | 91 | 61 | 9.5 | 0.6 |
| Minimum cost: 54% | 50 (32-69) | 96 (77-100) | 92 | 65 | 11.5 | 0.5 |
PPV indicates positive predictive value; NPV, negative predictive value; LR+, likelihood ratio of a positive result; and LR−, likelihood ratio of a negative result.